Effect of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator by Arya, A. et al.
E
i
a
A
M
M
F
o
I
C
m
f
i
D
M
M
I
1ffect of cardiac resynchronization therapy on the
ncidence of ventricular arrhythmias in patients with
n implantable cardioverter-defibrillator
rash Arya, MD, Majid Haghjoo, MD, Mohammad Reza Dehghani, MD,
ohammad Alasti, MD, Hormoz Alizadeh, MD, Babak Kazemi, MD,
ohammad Ali Sadr-Ameli, MD
rom the Department of Pacemaker and Electrophysiology, Rajaie Cardiovascular Medical and Research Center, School
f Medicine, Iran University of Medical Sciences, Tehran, Iran.BACKGROUND Cardiac resynchronization therapy (CRT) reduces mortality in selected patients with
heart failure. However, this result may not be entirely related to the beneficial hemodynamic effects of
CRT.
OBJECTIVES The purpose of this study was to assess retrospectively the effect of CRT on the incidence
of appropriate therapy in patients with an implantable cardioverter-defibrillator (ICD).
METHODS Sixty-five patients (48 men and 17 women; mean age 58  13 years) with an ICD (31
biventricular, 34 dual-chamber) were included in the study. Clinical, ECG, and ICD stored data and
electrograms were collected.
RESULTS Biventricular and dual-chamber ICDs were implanted in 31 and 34 patients, respectively,
who had either ischemic (n  36) or dilated cardiomyopathy (n  29). Thirty-two (49%) patients
received 1 appropriate ICD therapy during follow-up of 11  8 months. Thirty-five percent and 62%
of patients with biventricular (n  11) and dual-chamber ICDs (n  21), respectively, received
appropriate ICD therapy during the follow-up period (odds ratio  0.340, P  .048). Stratifying the
patients according to underlying heart disease and ejection fraction resulted in an adjusted odds ratio
 0.239 (P  .029). Comparing the rate of 1 appropriate ICD therapy between the two groups by
Kaplan-Meier analysis and the log rank test resulted in P  .027.
CONCLUSION In this retrospective analysis, biventricular pacing was associated with a decreased
incidence of sustained ventricular arrhythmias requiring ICD therapy. The antiarrhythmic effect of
biventricular pacing could contribute to the reduction in mortality reported in recent large-scale clinical
trials on CRT. However, further prospective studies are warranted to clarify this issue.
KEYWORDS Cardiac resynchronization therapy; Implantable cardioverter-defibrillator; Ventricular ar-
rhythmia; Heart failure
(Heart Rhythm 2005;2:1094–1098) © 2005 Heart Rhythm Society. All rights reserved.C
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ardiac resynchronization therapy (CRT) is an established
ode of therapy in selected symptomatic patients with heart
ailure due to systolic dysfunction.1 Recent large-scale clin-
cal trials of CRT have confirmed the favorable effects of
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547-5271/$ -see front matter © 2005 Heart Rhythm Society. All rights reservedRT on symptoms, quality of life, ventricular function, and
lood pressure and showed that CRT significantly reduces
ortality risk.2,3 Calculations based on data from the Car-
iac Resynchronization–Heart Failure trial showed that for
very nine biventricular pacemaker implanted, one death
nd three hospitalizations for major cardiovascular events
ere prevented.2 The reduction in mortality by CRT is at
east partly related to hemodynamic improvement.1
Some experimental studies have suggested that epicar-
ial pacing of the left ventricle in CRT prolongs the QT
nterval and increases the transmural dispersion of refracto-
iness.4 In addition, some cases of increased ventricular
rrhythmias following CRT have been reported.5,6 How-
. doi:10.1016/j.hrthm.2005.07.007
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1095Arya et al CRT and Incidence of Ventricular Arrhythmiaver, several clinical studies have suggested the opposite,
howing that CRT reduced mortality by decreasing the
ncidence of lethal ventricular arrhythmias.7–14
We conducted a retrospective case-control study to as-
ess the effect of CRT on the incidence of appropriate
herapy as a surrogate for sustained ventricular arrhythmias
see Definitions) in patients with an implantable cardio-
erter-defibrillator (ICD).
ethods
atient population
etween December 2002 and February 2005, 31 patients
nderwent transvenous biventricular ICD placement at our
enter. The left ventricular lead was implanted via thora-
otomy in two patients. All patients had QRS width 120
s and standard indication for CRT1 and ICD placement
see Definitions). During the same period, 68 patients with
oronary artery disease or dilated cardiomyopathy received
dual-chamber ICD at our center. From among these 68
atients, all individuals with QRS duration 120 ms (n 
4) were selected as the control group. Bradycardia pacing
f dual-chamber ICDs was programmed to VVI with a rate
f 40 bpm to prevent unnecessary ventricular pacing, except
n patients with established indications for cardiac pacing (n
5).15 All patients gave written informed consent for ICD
lacement. Mean patient age was 58  13 years. Basic
able 1 Baseline characteristics of patients
Variables ICD-DR† CRT-D¶ P-Value
umber 34 31 —
ollow-up period 11  8 10.3  6 0.455
ge (year) 57  13 58  12 0.849
ex:
Male 26 (76%) 22 (71%) 0.614
Female 8 (34%) 9 (29%)
nderlying heart disease:
Coronary artery disease 24 (70%) 12 (39%) 0.013
Dilated cardiomyopathy 10 (30%) 19 (61%)
VEF* (%) 26  8 22  6 0.013
RS duration (ms) 146  30 149  25 0.711
orrected QT interval (ms) 480  58 473  68 0.631
ndication of ICD
implantation (n):
Primary prevention 11 10 0.484
Secondary prevention 23 21
eta-blocker therapy (%) 53% 40% 0.250
CE‡ Inhibitors 88% 83% 0.371
miodarone 62% 53% 0.409
Left ventricular ejection fraction.
Dual chamber implantable cardioverter-defibrillator.
Angiotensin converting enzyme.
Implantable cardioverter-defibrillator with biventricular pacing option.haracteristics of the patients are given in Table 1. dCD data storage and retrieval
fter ICD placement, patients were followed on a regular
asis (3 months) and upon receiving high-voltage therapy in
ur outpatient ICD clinic. The devices were interrogated at
ach session, and the complete set of data (including intra-
ardiac electrograms) was recorded on floppy diskettes. The
ummary of the episodes also was recorded in the patient’s
le. The floppy diskettes were used in this study to retrieve
ll sustained arrhythmia episodes. Each episode was studied
y two independent electrophysiologists (AA and MRD) to
efine the diagnosis. In case of a discrepancy in diagnosis,
he final analysis of the arrhythmia episode was made by a
onsensus of three electrophysiologists (AA, MRD, and
H). In addition to the diagnosis, the time of arrhythmia
fter implantation and the mode of therapy were recorded.
efinitions
ppropriate ICD therapy was defined as antitachycardia
acing or shock therapy for ventricular tachycardia (VT) or
entricular fibrillation (VF). All patients who received
iventricular ICDs had standard indications for ICD place-
ent.16 Indication for ICD placement was defined as sec-
ndary prevention (n 44) in patients who had experienced
borted sudden cardiac death, sustained ventricular arrhyth-
ia, or syncope (n  9 with structural heart disease whose
lectrophysiologic study showed inducible, sustained, he-
odynamically unstable ventricular arrhythmias). The indi-
ation for ICD placement was categorized as primary pre-
ention in all other patients (n  21 with Multicenter
utomatic Defibrillator Implantation Trial [MADIT], Mul-
icenter Unsustained Tachycardia Trial [MUSTT]-like indi-
ations, i.e., patients with coronary artery disease [n  10]
nd asymptomatic patients with dilated cardiomyopathy [n
11] with nonsustained VT during Holter monitoring who
ad inducible, sustained, hemodynamically unstable ven-
ricular arrhythmia during electrophysiologic study).16
tatistical analysis
ariables are expressed as mean  SD and percentage.
ifferences in the frequency of characteristics were as-
essed by independent sample Student’s t-test for continu-
us variables. Chi-square test (or Fisher exact test if appli-
able) was used for discrete variables. Probability of 1
ppropriate ICD therapy based on the time to first appro-
riate ICD therapy between the two groups was determined
y Kaplan-Meier analysis with Mantel-Cox (log rank) test.
he time to first appropriate ICD therapy was plotted ac-
ording to the Kaplan-Meier method. The Mantel-Haenszel
est was used to generate the P value for reported odds
atios. Two-tailed P .05 was considered significant. SPSS
3.0 software (SPSS Inc., Chicago, IL, USA) was used for
ata storage and analysis.
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1096 Heart Rhythm, Vol 2, No 10, October 2005esults
aseline characteristics
ixty-five patients with biventricular and dual-chamber
CDs were followed for a mean 11  8 months. Biventricu-
ar and dual-chamber ICDs were placed in 31 and 34 pa-
ients, respectively. Characteristics of the patients with the
wo types of ICDs were compared (Table 1). Patients with
iventricular ICDs had lower left ventricular ejection frac-
ion (22  6 vs 26  8, P  .013) and higher prevalence of
ilated cardiomyopathy as the underlying heart disease
61% vs 30%, P  .013). Other variables between the two
roups were comparable.
ppropriate ICD therapy
hirty-two patients (49%) received 1 appropriate ICD
herapy during the follow-up period. VT and VF (based on
etection zones) were responsible for the first appropriate
CD therapy in 20 (62.5%) and 12 (27.5%) patients, respec-
ively. The proportion and cycle length of these ventricular
rrhythmias were comparable between the two groups (all P
S).
Thirty-five percent and 62% of patients with biventricu-
ar (n  11) and dual-chamber ICDs (n  21), respectively,
eceived appropriate ICD therapy during the follow-up pe-
iod (odds ratio 0.340, 95% confidence interval 0.125–
.935, P  .048). The mean number of appropriate ICD
herapies in patients with dual-chamber and biventricular
CDs was 13  32 (range 0–132) and 1.3  2.5 (range
–9), respectively (P  .047).
nteraction between ICD type and probability of
1 appropriate ICD therapy
igure 1 shows the comparison of differences in 1 appro-
riate ICD therapy using Kaplan-Meier survival curves for
he two device groups, with application of Mantel-Cox (log
ank) test (P .027). Among 34 patients with dual-chamber
CDs and 31 patients with biventricular ICDs, 62% and 35%
eceived appropriate ICD therapy, respectively (odds ratio
0.340, 95% confidence interval  0.125–0.935, P 
048). Analysis was repeated by stratifying patients accord-
ng to underlying heart disease and left ventricular ejection
raction. The subgroups of left ventricular ejection fraction
ere divided based on the median value (25%) in the study
opulation. The adjusted odds ratio was 0.239 (95% confi-
ence interval  0.1–0.84, P  .029).
revalence and number of nonsustained VTs
orty-eight patients (74%) had nonsustained VT during the
ollow-up period. A trend toward higher prevalence of non-
ustained VT in patients with dual-chamber ICDs vs those
ith biventricular ICDs (80% vs 68%) failed to reach sta- oistical significance (P  .258). A trend toward a higher
ean number of nonsustained VTs in patients with dual-
hamber ICDs (155  394 [range 1–1,642] vs 33  95
range 1–436]) also failed to reach statistical significance (P
.113).
We assumed that the differences in baseline characteris-
ics may have biased these findings (Table 1). To adjust for
ifferences in baseline characteristics, we divided the pa-
ients into two groups based on the median number of
onsustained VTs in the cohort (median  3) and repeated
he analysis by stratifying for ejection fraction and under-
ying heart disease. This analysis yielded an adjusted Man-
el-Haenszel P  .059 (2  3.561). A correlation was
ound between total number of nonsustained VTs and total
umber of appropriate ICD therapies (Pearson r  0.964, P
.01).
iscussion
ain findings
iventricular pacing decreased the rate of appropriate ICD
herapy (including both antitachycardia pacing and shock)
y suppressing the occurrence of sustained ventricular ar-
hythmias requiring ICD therapy. During the follow-up pe-
iod, patients with biventricular ICDs received 66% fewer
ppropriate ICD therapies compared to patients with dual-
hamber ICDs (Figures 1 and 2).
The recent clinical trials on CRT confirmed that CRT
ignificantly reduces the risk of death.2,3 However, the re-
uction in mortality may not be related entirely to the
avorable hemodynamic effects of CRT. Several potential
echanisms may explain the observed antiarrhythmic effect
igure 1 Kaplan-Meier plot of the time to the first inappropriate
herapy according to ICD type. Log rank (Mantel-Cox) test was
sed to generate the P value. CRT-D  biventricular implantable
ardioverter-defibrillator; ICD-DR  dual-chamber implantable
ardioverter-defibrillator.f CRT.
t
f
a
I
c
a
r
S
c
v
r
t
r
t
i
t
t
n
m
o
a
t
v
r
r
a
o
h
s
m
c
C
a
l
H
t
H
v
s
s
o
O
b
p
e
s
w
w
e
i
b
s
d
t
F
a
g
t
g
C
p
o
i
(
s
w
i
C
T
t
t
S
W
A
p
a
e
t
F
a
U
T
v

d
1097Arya et al CRT and Incidence of Ventricular ArrhythmiaAlthough we did not assess the hemodynamic response
o CRT in our study, improvement in left ventricular per-
ormance could partly explain the decreased incidence of
ppropriate ICD therapy in patients with biventricular
CDs.14,17,18 Hemodynamic improvement following CRT
ould decrease the stretch on myocardium and modulate
utonomic nervous system activity, which in turn would
educe the incidence of lethal ventricular arrhythmias.14,18
everal studies have shown that biventricular pacing de-
reases the frequency of ventricular ectopy.7,10 Reducing
entricular ectopy that can trigger sustained ventricular ar-
hythmias could decrease the incidence of sustained ven-
ricular arrhythmias and appropriate ICD therapy.
Several studies have shown that biventricular pacing
educes the inducibility of VT.9–11 Kowal et al9 evaluated
he acute electrophysiologic effects of biventricular pacing
n a prospective randomized study. They showed that biven-
ricular compared with right ventricular programmed elec-
rical stimulation significantly reduced induction of VT (but
ot VF). They hypothesized that the mechanism of arrhyth-
ia suppression by biventricular pacing was preexcitation
f the area of slow conduction responsible for reentrant
rrhythmias and significant increase in the local left ven-
ricular coupling interval.9
Experimental studies have suggested that epicardial left
entricular pacing increases the transmural dispersion of
efractoriness, hence biventricular pacing may cause proar-
hythmia in selected patients with CRT.4,14 Berger et al13
ssessed the effect of biventricular pacing on ECG markers
f ventricular repolarization in patients with congestive
eart failure. Using high-resolution surface ECG, they
howed that biventricular pacing significantly reduced ECG
igure 2 Effect of biventricular pacing on the incidence of
ppropriate implantable cardioverter-defibrillator (ICD) therapy.
nadjusted odds ratios and 95% confidence intervals are shown.
he subgroups of age, ejection fraction, and QRS width are di-
ided based on the median values of the study population. CRT-D
biventricular implantable cardioverter-defibrillator; ICD-DR 
ual-chamber implantable cardioverter-defibrillator.arkers of ventricular dispersion of repolarization, which dould contribute further to the antiarrhythmic effects of
RT.
In a similar study to ours, Higgins et al7 showed that
ppropriate ICD therapy was less common with biventricu-
ar ICDs in patients with standard indications for ICDs.
owever, several points merit consideration. All left ven-
ricular leads were placed via thoracotomy in the study by
iggins et al, whereas left ventricular leads were positioned
ia the coronary sinus in all but two of our patients. In the
tudy by Higgins et al, only 32 of 54 patients (59%) were
uitable for the final paired analysis, and the period of
bservation in each mode of pacing was only 3 months.17
ur study with a larger patient population confirmed the
eneficial effect of biventricular pacing in reducing appro-
riate ICD therapy during a longer follow-up period. How-
ver, ICD therapy should not be equated with a reduction in
udden cardiac death. Therefore, larger prospective studies
ith cardiac and all-cause mortality as the endpoints are
arranted to clarify this issue.
Although the bulk of evidence favors antiarrhythmic
ffects of CRT,7–14 several case reports have shown an
ncreased incidence of ventricular arrhythmia following
iventricular pacing or ICD placement.5,6 In addition, de-
pite a statistically significant lower absolute number of
eaths classified as sudden in the CRT group compared with
he control group in the Cardiac Resynchronization–Heart
ailure study, the proportion of deaths that were classified
s sudden cardiac death was comparable between the two
roups. The mode of death was classified as sudden in 38 of
he 120 patients (32%) who died in the medical therapy
roup and in 29 of the 82 patients (35%) who died in the
RT group.2
Although the underlying mechanism(s) in the case re-
orts mentioned are not clear, physicians should be aware of
ccasional proarrhythmic effects of CRT. Biventricular pac-
ng-induced VT is one of the study endpoints of PACMAN
Pacing for Cardiomyopathies, a European study), a pro-
pective single-blind study ongoing in Europe. This study
ill help determine the incidence of biventricular pacing-
nduced VT.6
linical implication
he antiarrhythmic effect of biventricular pacing could con-
ribute to the reduction in mortality observed in CRT pa-
ients.
tudy limitation
e did not record and assess the effect of New York Heart
ssociation (NYHA) functional class on the rate of appro-
riate ICD therapy. Patients are more likely to receive
ppropriate ICD therapy if they have lower left ventricular
jection fraction and higher NYHA functional class.7 Al-
hough we adjusted our analyses for ejection fraction, we
id not record the NYHA functional class of the patients.
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1098 Heart Rhythm, Vol 2, No 10, October 2005his could have resulted in underestimation of the beneficial
ffect of CRT on the incidence of ventricular arrhythmias
uring follow-up, as we would expect a higher NYHA
unctional class in the biventricular ICD group. Finally, it is
ossible that after VT detection and appropriate ICD dis-
harge, electrical and/or medical treatment was adjusted or
ptimized to prevent new VT recurrences. However, to
inimize this effect, we only compared the occurrence of
1 appropriate ICD therapy between the two groups rather
han the total number of appropriate ICD therapies.
onclusion
n selected patients with heart failure with standard indica-
ions for ICD placement, biventricular pacing reduced the
ncidence of appropriate ICD therapy as a surrogate for
ustained ventricular arrhythmias. Further large-scale pro-
pective studies assessing the potential antiarrhythmic ef-
ects of CRT are warranted.
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